CKPT - チェックポイント・セラピュ―ティクス (Checkpoint Therapeutics Inc.) チェックポイント・セラピュ―ティクス



symbol CKPT
会社名 Checkpoint Therapeutics Inc (チェックポイント・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Checkpoint Therapeutics Inc. is an immuno-oncology biopharmaceutical company. The Company is focused on the acquisition development and commercialization of non-chemotherapy immune-enhanced combination treatments for patients with solid tumor cancers. The Company is engaged in developing a portfolio of human immuno-oncology targeted antibodies. The portfolio of antibodies that it licensed includes antibodies targeting programmed death-ligand 1 (PD-L1) glucocorticoid-induced Tumor necrosis factor receptor (TNFR) related protein (GITR) and carbonic anhydrase IX (CAIX). It focuses on developing the immuno-oncology and checkpoint inhibitor antibodies. It is developing three oral small molecules targeted anti-cancer agents consisting of an inhibitor of epidermal growth factor receptor (EGFR) mutations an inhibitor of the bromodomain and extra-terminal (BET) protein BRD4 and an inhibitor of poly (ADP-ribose) polymerase (PARP). Its pipeline of products includes CK-101 and CK-103.   チェックポイント・セラピュ―ティクスは米国のバイオ医薬品企業。主にがん腫瘍を治療するための非化学療法や免疫療法の開発・商業化に従事する。認可された同社の抗体ポ―トフォリオには、グルココルチコイド誘発TNFR関連タンパク質および炭酸脱水酵素を標的とする抗体が含まれる。また、経口抗がん療法も開発する。本社所在地はニューヨーク。   Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company which focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers.
本社所在地 2 Gansevoort Street 9th Floor New York NY 10014 USA
電話番号 +1 212-554-4366
設立年月日 41944
市場名 NASDAQ Small Cap
ipoyear ―年
EBITDA EBITDA(百万ドル) -27.35000
終値(lastsale) 3.32
時価総額(marketcap) 106598108.48
時価総額 時価総額(百万ドル) 89.25986
売上高 売上高(百万ドル) 1.15100
企業価値(EV) 企業価値(EV)(百万ドル) 60.95586
当期純利益 当期純利益(百万ドル) -27.25000
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Checkpoint Therapeutics Inc revenues decreased 55% to $470K. Net loss increased 42% to $15.4M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development - Balancin increase of 76% to $12.1M (expense) General and administrative - Balanci increase of 53% to $2.6M (expense).



   Checkpoint Therapeutics beats by $0.09, misses on revenue  2019-05-09
Checkpoint Therapeutics (NASDAQ: CKPT ): Q1 GAAP EPS of -$0.18 beats by $0.09 . More news on: Checkpoint Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more …
   Checkpoint up 5% on positive cosibelimab data  2019-05-01
Preliminary data from a Phase 1 clinical trial assessing Checkpoint Therapeutics' ( CKPT +5% ) lead immuno-oncology candidate cosibelimab (formerly CK-301) showed a treatment effect. More news on: Checkpoint Therapeutics, Inc., Merck & Co., Inc., Bristol-Myers Squibb Company, He…

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 チェックポイント・セラピュ―ティクス CKPT Checkpoint Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)